PATH Stock Slips As UBS Trims Price Target

UiPath Inc. stocks have been trading up by 7.29 percent amid upbeat sentiment surrounding its expanding AI automation capabilities.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading PATH

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

UBS lowered its price target on UiPath from $13 to $12 while keeping a Neutral stance.
Street consensus on PATH is still Hold, with a mean target near $13.47.
Shares of PATH trade around $10.81, leaving only modest implied upside.
Recent trading shows PATH grinding higher off lows but still stuck in a tight range.

Quick Financial Overview

UiPath Inc. gives traders a classic mixed picture. On the one hand, PATH is finally putting up real profits. On the other, Wall Street is dialing back expectations.

PATH generated about $1.61B in annual revenue, growing at a double‑digit pace over the past three to five years. Gross margin sits near 83%, which is very high. That tells traders the core automation software is lucrative once it is sold and deployed. UiPath also turned in quarterly net income of about $22.5M with diluted EPS of $0.04, while free cash flow around $129M shows the business is throwing off cash, not burning it.

More Breaking News

The balance sheet is another plus for PATH. Long‑term debt is only about $72M against total equity near $1.9B, with a current ratio of 2.3. In simple terms, UiPath has more than enough liquid assets to cover short‑term bills. Valuation is no longer nose‑bleed: a P/E near 17 and price‑to‑sales around 3.2 put PATH closer to a normal software name instead of a hype stock, which matters as trading shifts from story to fundamentals.

Why Traders Are Watching PATH After The UBS Cut

The latest headline around PATH comes from UBS, and it is not the kind of news that sparks a squeeze. UBS cut its UiPath price target from $13 to $12 and reiterated a Neutral rating. At the same time, the broader Street still sits at a Hold stance with an average target of about $13.47, compared with a recent price around $10.81. For active traders, that setup screams “tempered expectations.”

PATH once traded at wild multiples; those days are gone. Now the story is whether UiPath can grow into a steady, profitable automation platform while the stock grinds in a range. Over the last few weeks, PATH has bounced between roughly $10.20 and $12.55. The most recent daily close near $11.62 shows price working its way back from a sharp drop on 2026/07/22, when shares slid from above $12 to the low $10s. That kind of flush‑and‑grind pattern is where patient traders often look for clear levels.

Zoom in on the intraday tape and PATH shows tight consolidation. Most 5‑minute candles sit between $11.45 and $11.65, with volume pushing price in small waves instead of big spikes. That tells traders algos and funds are in control, not emotional chase money. With UBS trimming the target and no strong bullish catalyst in sight, PATH is a name to stalk, not to force. The edge will come from reacting to breaks of well‑defined support and resistance, not from guessing what analysts do next.

Conclusion

For UiPath Inc. and PATH traders, the UBS move is a reality check. A cut from $13 to $12, combined with a Hold consensus and a mean target near $13.47, says the Street sees some upside but not a runway of easy gains. With PATH sitting around $10.81–$11.62, the implied reward is real but limited, especially if growth slows or margins slip.

At the same time, the fundamentals underneath PATH are much stronger than they were during the hype phase. UiPath is profitable, cash‑flow positive, and lightly leveraged. That combination often builds a floor under a stock, even when analysts turn cautious. For short‑term trading, the action in PATH is all about levels: the $10 area as a key support from the July flush, and the $12–$12.50 zone as clear overhead supply from repeated rejections. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” In PATH’s case, volume around those key levels, the broader trend in automation names, and catalysts like earnings or guidance shifts are what will separate solid day trades from forced guesses.

Traders who follow Tim Sykes’ style will recognize the playbook here: “The market doesn’t care about your opinion, only price action and risk management.” PATH fits that mindset. Use the UBS downgrade and tight range as a framework, not a forecast. Study the chart, respect the risk, and let UiPath’s next big move prove itself on the screen before committing real capital. This analysis is for educational and research purposes only, not trading advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!